Results 161 to 170 of about 72,448 (283)

On 3‐MMC: A Cathinone I Have Come to Know and Love

Anthropology of Consciousness, EarlyView.
ABSTRACT This article attempts to complicate the mythology of a compound in a state of becoming. I will trace lightly its origins as a cultural disruptor and how I am implicated in this imperative. Introducing you to 3‐MMC will require multiple modes of storytelling and taking of liberties, drawing on literature reviews, practice‐based research, prose,
Carmen Ostrander
wiley   +1 more source

Predicting drug-drug interactions between ayahuasca alkaloids and SSRIs using physiologically based pharmacokinetic modeling. [PDF]

Front Mol Biosci
Ribeiro GSG, Paranhos BAPB, Dörr F, Yonamine M, Villanova B, Guerra LTL, Raminelli AO, Reis JAS, de Paula CC, Zacharias ABV, Cecílio Hallak JE, Dos Santos RG, Martins FS, Marcourakis T.   +13 more
europepmc   +1 more source

Safety pharmacology of acute mescaline administration in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aims Psychedelics, including mescaline, may serve as novel treatments for depression and anxiety. However, data is scarce on the safety of mescaline. Methods The present pooled analysis included two double‐blind, randomized, placebo‐controlled studies with a total of 48 participants and 96 mescaline administrations. Single oral‐dose administrations (n =
Aaron Klaiber, Mélusine Humbert‐Droz, Laura Ley, Yasmin Schmid, Matthias E. Liechti   +4 more
wiley   +1 more source

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial. [PDF]

Nat Med
Erritzoe D, Barba T, Benway T, Joel Z, Good M, Layzell M, Jones MB, Campbell G, Murphy-Beiner A, Rands P, Boyce M, Topping H, Weiss B, Timmermann C, Nutt D, Carhart-Harris R, Routledge C, James E.   +17 more
europepmc   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, EarlyView.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Evaluating use of disease-modifying therapies for multiple sclerosis using claims data. [PDF]

Front Health Serv
Wang X, Zhao FL, Newby D, Li S.
europepmc   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, EarlyView.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Toxicometabolomics Characterization of Two N1-Sulfonated Dimethyltryptamine Derivatives in Zebrafish Larvae and Human Liver S9 Fractions Using Liquid Chromatography-High-Resolution Mass Spectrometry. [PDF]

Metabolites
Punnamraju P, Manier SK, Hemmer S, Grill M, Schippers P, Herrmann J, Meyer MR.   +6 more
europepmc   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source

Treatment evolution in spinal muscular atrophy: insights from the SMArtCARE registry. [PDF]

Brain
Voigt-Müller C, Pfaffenlehner M, Bernert G, Cetin H, Hagenacker T, Kölbel H, Lochmüller H, Pfeuffer C, Vill K, Walter MC, Kirschner J, Pechmann A, SMArtCARE study group .   +12 more
europepmc   +1 more source